JP2015527374A - アジュバント癌治療の方法 - Google Patents

アジュバント癌治療の方法 Download PDF

Info

Publication number
JP2015527374A
JP2015527374A JP2015530072A JP2015530072A JP2015527374A JP 2015527374 A JP2015527374 A JP 2015527374A JP 2015530072 A JP2015530072 A JP 2015530072A JP 2015530072 A JP2015530072 A JP 2015530072A JP 2015527374 A JP2015527374 A JP 2015527374A
Authority
JP
Japan
Prior art keywords
melanoma
treatment
dabrafenib
trametinib
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015530072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015527374A5 (enExample
Inventor
ラクエーレ，シルヴィ
エフ． レボヴィッツ，ピーター
エフ． レボヴィッツ，ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015527374(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of JP2015527374A publication Critical patent/JP2015527374A/ja
Publication of JP2015527374A5 publication Critical patent/JP2015527374A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015530072A 2012-09-04 2013-08-30 アジュバント癌治療の方法 Pending JP2015527374A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261696375P 2012-09-04 2012-09-04
US61/696,375 2012-09-04
PCT/US2013/057432 WO2014039375A1 (en) 2012-09-04 2013-08-30 Method of adjuvant cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017216933A Division JP6511117B2 (ja) 2012-09-04 2017-11-10 アジュバント癌治療の方法

Publications (2)

Publication Number Publication Date
JP2015527374A true JP2015527374A (ja) 2015-09-17
JP2015527374A5 JP2015527374A5 (enExample) 2016-10-06

Family

ID=50237545

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015530072A Pending JP2015527374A (ja) 2012-09-04 2013-08-30 アジュバント癌治療の方法
JP2017216933A Active JP6511117B2 (ja) 2012-09-04 2017-11-10 アジュバント癌治療の方法
JP2019072361A Active JP6684941B2 (ja) 2012-09-04 2019-04-05 アジュバント癌治療の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017216933A Active JP6511117B2 (ja) 2012-09-04 2017-11-10 アジュバント癌治療の方法
JP2019072361A Active JP6684941B2 (ja) 2012-09-04 2019-04-05 アジュバント癌治療の方法

Country Status (20)

Country Link
US (6) US20150216868A1 (enExample)
EP (2) EP3981408A1 (enExample)
JP (3) JP2015527374A (enExample)
KR (1) KR102134585B1 (enExample)
CN (2) CN104582706A (enExample)
AU (2) AU2013313050A1 (enExample)
BR (1) BR112015004578A2 (enExample)
CA (1) CA2882437C (enExample)
CY (1) CY1124812T1 (enExample)
DK (1) DK2892535T3 (enExample)
ES (1) ES2900825T3 (enExample)
HR (1) HRP20211817T1 (enExample)
HU (1) HUE056646T2 (enExample)
IN (1) IN2015KN00449A (enExample)
LT (1) LT2892535T (enExample)
PL (1) PL2892535T3 (enExample)
PT (1) PT2892535T (enExample)
RU (1) RU2640180C2 (enExample)
SI (1) SI2892535T1 (enExample)
WO (1) WO2014039375A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104582706A (zh) 2012-09-04 2015-04-29 葛兰素史克有限责任公司 辅助癌症治疗的方法
EP3378952B1 (en) 2013-12-28 2020-02-05 Guardant Health, Inc. Methods and systems for detecting genetic variants
CA3037456A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
IL270224B1 (en) * 2017-05-02 2024-04-01 Novartis Ag Combination therapy employing trametinib and a defined raf inhibitor
WO2019204399A1 (en) * 2018-04-17 2019-10-24 The University Of Chicago Methods and compositions for treating cancer
CN109106893B (zh) * 2018-11-12 2021-04-20 上海市中西医结合医院 一种调节肠道屏障功能的中药复方制剂及其制备方法
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
EP4073102A4 (en) * 2019-12-12 2024-05-08 Ting Therapeutics LLC Compositions and methods for the prevention and treatment of hearing loss
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011047238A1 (en) * 2009-10-16 2011-04-21 Glaxosmithkline Llc Combination
WO2012095505A1 (en) * 2011-01-12 2012-07-19 Boehringer Ingelheim International Gmbh Anticancer therapy with dual aurora kinase / mek inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1761528E (pt) 2004-06-11 2008-04-15 Japan Tobacco Inc Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
SG166775A1 (en) * 2005-02-18 2010-12-29 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN104582706A (zh) 2012-09-04 2015-04-29 葛兰素史克有限责任公司 辅助癌症治疗的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011047238A1 (en) * 2009-10-16 2011-04-21 Glaxosmithkline Llc Combination
WO2012095505A1 (en) * 2011-01-12 2012-07-19 Boehringer Ingelheim International Gmbh Anticancer therapy with dual aurora kinase / mek inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF TRANSLATIONAL MEDICINE, vol. 10(85), JPN6016039642, May 2012 (2012-05-01), pages 1 - 9, ISSN: 0003419634 *

Also Published As

Publication number Publication date
CY1124812T1 (el) 2022-11-25
US10869869B2 (en) 2020-12-22
KR20150047619A (ko) 2015-05-04
EP3981408A1 (en) 2022-04-13
JP6511117B2 (ja) 2019-05-15
CN104582706A (zh) 2015-04-29
SI2892535T1 (sl) 2022-01-31
IN2015KN00449A (enExample) 2015-07-17
CA2882437C (en) 2021-03-02
EP2892535A1 (en) 2015-07-15
PT2892535T (pt) 2021-12-15
EP2892535B1 (en) 2021-09-22
US20200054641A1 (en) 2020-02-20
BR112015004578A2 (pt) 2017-07-04
HUE056646T2 (hu) 2022-02-28
AU2016244279A1 (en) 2016-11-03
US20180338979A1 (en) 2018-11-29
AU2016244279B2 (en) 2018-01-04
EP2892535A4 (en) 2016-04-13
AU2013313050A1 (en) 2015-03-26
US20210060021A1 (en) 2021-03-04
LT2892535T (lt) 2021-12-10
RU2015105821A (ru) 2016-10-20
WO2014039375A1 (en) 2014-03-13
JP6684941B2 (ja) 2020-04-22
JP2018058859A (ja) 2018-04-12
HRP20211817T1 (hr) 2022-03-04
US20150216868A1 (en) 2015-08-06
JP2019142899A (ja) 2019-08-29
US20230330091A1 (en) 2023-10-19
ES2900825T3 (es) 2022-03-18
KR102134585B1 (ko) 2020-07-17
HK1206642A1 (en) 2016-01-15
PL2892535T3 (pl) 2022-01-31
CN107308164A (zh) 2017-11-03
DK2892535T3 (da) 2022-01-03
CA2882437A1 (en) 2014-03-13
US20170202842A1 (en) 2017-07-20
RU2640180C2 (ru) 2017-12-26

Similar Documents

Publication Publication Date Title
JP6684941B2 (ja) アジュバント癌治療の方法
JP2015518888A (ja) 腫瘍疾患を治療するための１７−アルファ−ヒドロキシラーゼ（ｃ１７，２０−リアーゼ）インヒビターと特定のｐｉ−３ｋインヒビターとの組み合わせ
US20250041298A1 (en) Cdk4 inhibitor for the treatment of cancer
JP2020519576A (ja) 肝細胞癌の治療
JP2025509278A (ja) 小細胞肺癌を治療する方法
CN111728974B (zh) 西奥罗尼用于小细胞肺癌的治疗
US20210205272A1 (en) Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3
HK40070843A (en) Dabrafenib and trametinib in a method of adjuvant cancer treatment
US20220073642A1 (en) Methods of using surufatinib in treating advanced pancreatic and extra-pancreatic neuroendocrine tumors
CN118338901A (zh) 用于治疗癌症的cdk4抑制剂
HK1206642B (en) Method of adjuvant cancer treatment
RU2728932C2 (ru) Терапевтическое средство для лечения рака желчевыводящих путей
CN118354772A (zh) 治疗头颈癌的方法

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160818

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20160818

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20160914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170711